stockrow
Friday 6 November 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
26.82
1.03
+3.99%
Follow VKTX
Alert me
Viking Therapeutics, Inc. (VKTX) Net income
Viking Therapeutics, Inc.'s net income for fiscal 2025 was −$359.6M, compared with −$110.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$627.2M. Over the past ten years it has ranged from −$359.6M (fiscal 2025) to −$14.7M (fiscal 2016) — the current reading is the lowest in ten years. Net income has fallen for 9 consecutive fiscal years. Viking Therapeutics, Inc. ranks 595th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$359.6M | — |
| FY2024 | −$110.0M | — |
| FY2023 | −$85.9M | — |
| FY2022 | −$68.9M | — |
| FY2021 | −$55.0M | — |
| FY2020 | −$39.5M | — |
| FY2019 | −$25.8M | — |
| FY2018 | −$22.1M | — |
| FY2017 | −$20.6M | — |
| FY2016 | −$14.7M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$183.2M | — |
| Jun 2026 | −$128.0M | — |
| Mar 2026 | −$158.3M | — |
| Dec 2025 | −$157.7M | — |
| 43 more quarters | Free account |
Against its own ten years
Low −$359.6M
High −$14.7M
Ten-year median
−$39.5M
Current reading's percentile
9
Net income against peers
| Company | Net income |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $362.2M |
| ELVN Enliven Therapeutics, Inc. compare | −$105.9M |
| PBLS Parabilis Medicines, Inc. compare | −$170.9M |
| CELC Celcuity, Inc. compare | −$226.5M |
| IRON Disc Medicine, Inc. compare | −$245.9M |
| XENE Xenon Pharmaceuticals Inc. compare | −$409.2M |
| DYN Dyne Therapeutics, Inc. compare | −$519.4M |
| VKTX Viking Therapeutics, Inc. | −$627.2M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$702.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item